Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Dr. Reddy's: No looking back - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • May 30, 2001

    Dr. Reddy's: No looking back

    Dr. Reddy's has recorded a net profit of Rs 1.3 bn in FY01. The results for the current year include consolidated figures for Cheminor Drugs and hence are not comparable with FY00. Operating profit margins have showed a marked improvement compared to our projections.

    (Rs m) FY00 FY01 % change
    Sales 4,930 8,324 68.8%
    Other Income 49 161 228.6%
    Expenditure 4,001 6,048 51.2%
    Operating Profit (EBDIT) 929 2,276 145.0%
    Operating Profit Margin (%) 18.8% 27.3%
    Interest 141 358 153.9%
    Depreciation 169 437 158.6%
    Profit before Tax 668 1,642 145.8%
    Tax 65 300 361.5%
    Profit after Tax/(Loss) 603 1,342 122.6%
    Net profit margin (%) 12.2% 16.1%
    No. of Shares (eoy) (m) 26.5 37.4  
    Diluted Earnings per share* 22.8 35.9  
    P/E (at current price) 62.1 39.4  
    (* after ADR dilution)

    On a comparative basis, net profit has improved by 54% on the back of a 25% increase in gross turnover. Exports now account for almost 50% of the total turnover on a consolidated basis. Operating profit margins have shown a marked improvement of more than 600 basis points on a comparative basis. The net profit declared by the company is more or less as per market expectations.

    R&D expenses showed a noteworthy increase of 87% to 610 m, constituting 7% of turnover. Dr. Reddy announced a licensing agreement with Novartis Pharma AG for its anti-diabetic molecule against which the company would receive US$ 55 m as up-front and milestone payments. Besides, the company also has a very strong R&D coffer, which is expected to deliver results in the time to come.

    Dr. Reddy is targeting huge US generic market for rapid growth. The generic business unit has contributed a maiden Rs 300 m in FY01. Cheminor Drugs (now merged with Dr. Reddy) has a string of generic products in the pipeline for the lucrative US markets. In a related development, the company has recently received ANDA approval for marketing generic version of Famotidine. Dr. Reddy has filed for a six month generic marketing exclusivity for fluoxetine, an anti-depression drug with the US FDA. We expect that Dr. Reddy's may mop up an additional US$ 40 m revenues in FY02 if its able to bag the six month exclusivity rights. Dr. Reddy stands a strong chance of getting the exclusive rights.

    The company has recently raised US$ 115.5 m from ADR proceeds, diluting 18% of the company's equity. It plans to use these proceeds for R&D (US$ 30 m) and acquisitions to fuel inorganic growth. We expect that with ADR fund deployment and milestone receipts the company would be able to take a step towards self sufficiency in its R&D work.

    At the current market price of Rs 1,413 the company is trading at a P/E of 40 times its fully diluted earnings for FY01 earnings (after taking into account ADR dilution). There are number of valuation triggers for the company at this point of time viz. windfall revenue gains from its research pipeline, US generic market earnings visibility, inorganic growth from ADR funds, further unlocking of intellectual property, strong core business fundamentals etc. However, at 40 times its FY01 earnings, the markets seem to have built in lot of expectations from the company. The flip side thus is that any negative news either from the US generic market or on the R&D front could lead to a fall in valuations. Again, any delay in deployment of ADR funds, could impact Return on capital employed (ROCE) negatively in the near term.



    Equitymaster requests your view! Post a comment on "Dr. Reddy's: No looking back". Click here!


    More Views on News

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

    Sep 12, 2016

    Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)


    • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts